Last reviewed · How we verify
Urinary Kallikrein
Urinary kallikrein is a serine protease that cleaves kininogen to release bradykinin, a potent vasodilator and natriuretic peptide that lowers blood pressure and improves renal perfusion.
Urinary kallikrein is a serine protease that cleaves kininogen to release bradykinin, a potent vasodilator and natriuretic peptide that lowers blood pressure and improves renal perfusion. Used for Hypertension, Renal protection in hypertensive patients.
At a glance
| Generic name | Urinary Kallikrein |
|---|---|
| Also known as | Urinary Kallidinogenase |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Serine protease / Kinin-kallikrein system activator |
| Target | Kininogen (substrate); B1 and B2 bradykinin receptors (downstream) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Kallikrein activates the kinin-kallikrein system, which generates bradykinin—a short-lived peptide that acts on B1 and B2 receptors to promote vasodilation, increase sodium and water excretion, and reduce vascular resistance. This mechanism helps normalize blood pressure and improve renal hemodynamics, particularly in hypertensive patients. The urinary form is derived from or administered as a biological extract to harness these endogenous regulatory pathways.
Approved indications
- Hypertension
- Renal protection in hypertensive patients
Common side effects
- Hypotension
- Hyperkalemia
- Cough
- Angioedema
Key clinical trials
- Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke (NA)
- Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS) (PHASE2)
- Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment (NA)
- Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion (NA)
- Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS) (NA)
- Study to Assess PK, Safety and Tolerability in Healthy Subjects (PHASE1)
- Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke (NA)
- Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: